Associated Papers
A comprehensive functional atlas of ALK kinase domain variants reveals resistance landscape to ALK inhibitors.
Oh HC et al.
Genome Biology, 2026
Diverse Resistant Mechanisms Identified Using Serial Next-Generation Sequencing in a Patient With ALK-Rearranged Metastatic Lung Adenocarcinoma: A Case Report.
Saw SPL et al.
Jto Clinical and Research Reports, 2023
Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors.
Kwon M et al.
Cancer Medicine, 2022
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
34630336 (PubMed )
Supplement: Table_1.xlsx › Tab2
Ceritinib ALK T1151R Resistance Mutation in Lung Cancer With Initial Response to Brigatinib.
Mehlman C et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2019
Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.
Yu Y et al.
Lung Cancer (amsterdam, Netherlands), 2019
Genetic susceptibility to neuroblastoma: current knowledge and future directions.
Ritenour LE et al.
Cell and Tissue Research, 2018
Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
Noh KW et al.
The Journal of Pathology, 2017
TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.
Amin AD et al.
Oncotarget, 2016
ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome.
Bourdeaut F et al.
European Journal of Human Genetics : Ejhg, 2012
Select a paper to view details